Company News

Alembic Pharmaceuticals receives USFDA Final Approval for Vardenafil Hydrochloride Tablets

  • Posted on: 6 August 2020
  • By: PharmaTutor News

Alembic Pharmaceuticals Limited announced that the Company has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Vardenafil Hydrochloride Tablets, 2.5 mg (base), 5 mg (base), 10 mg (base), and 20 mg (base).

AbbVie announces Positive Phase 3 Data for Atogepant in Migraine Prevention

  • Posted on: 31 July 2020
  • By: PharmaTutor News

AbbVie announced that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) met its primary endpoint of statistically significantly greater reduction in mean monthly migraine days, compared to placebo, for all doses across the 12-week treatment period.